Activation of coagulation and fibrinolysis has been observed in many tumors. Our study aimed to investigate the clinical and prognostic significance of various plasma coagulation tests in patients with cervical cancer. A total of 296 patients with cervical cancer were included in the analysis. Patients were followed up for at least 60 months until death. Pretreatment parameters including activated partial thromboplastin time, D-dimer, fibrinogen, prothrombin time, thrombin time, lactate dehydrogenase, and squamous cell carcinoma antigen were evaluated. Prothrombin time (hazard ratio = 1.825; P = 0.006) and plasma D-dimer levels (hazard ratio = 2.179; P = 0.036) were identified as significant independent predictors of overall survival. Patients with elevated D-dimer levels had a significantly shorter overall survival compared with those with low-D-dimer levels (<0.5 μg/ml) in the stage I subgroup (n = 98, P = 0.019) and stage II subgroup (n = 77, P = 0.044). D-dimer levels differed significantly according to mortality (P < 0.001), stage I versus stage II (P = 0.030), and stage I versus stage III/IV (P = 0.038). DD level of patients with chemotherapy and/or radiotherapy was higher than patients with other treatment (P < 0.001). Patients with a low-D-dimer level (<0.5 μg/ml) showed a significantly better 5-year overall survival (OS) compared with patients with an increased D-dimer level for different histological typing of squamous cell carcinoma (SCC) (P = 0.001) and non-SCC (P < 0.043). In conclusion, the pretreatment plasma D-dimer level is a potential prognostic factor for cervical cancer.
Cervical cancer Coagulation Prothrombin time D-dimer Prognosis
This is a preview of subscription content, log in to check access.
We thank the Director of Clinical Laboratories, Sun Yat-sen University Cancer Center, Guangzhou, China, Prof. Wan-Li Liu, for providing support on research conditions in this study and making substantial contributions to its conception and design.
Conflicts of interest
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
Benedet JL, Odicino F, Maisonneuve P, et al. Carcinoma of the cervix uteri. J Epidemiol Biostat. 2001;6:7–43.PubMedGoogle Scholar
Chen J, Macdonald OK, Gaffney DK. Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix. Obstet Gynecol. 2008;111(6):1394–402.CrossRefPubMedGoogle Scholar
Intaraphet S, Kasatpibal N, Siriaunkgul S, et al. Prognostic impact of histology in patients with cervical squamous cell carcinoma, adenocarcinoma and small cell neuroendocrine carcinoma. Asian Pac J Cancer Prev. 2013;14(9):5355–60.CrossRefPubMedGoogle Scholar
Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumor markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol. 2008;66:10–20.CrossRefPubMedGoogle Scholar
Reesink-Peters N, van der Velden J, Ten Hoor KA, Boezen HM, de Vries EG, Schilthuis MS, et al. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer. J Clin Oncol. 2005;23:1455–62.CrossRefPubMedGoogle Scholar
Langer F, Holstein K, Eifrig B, Bokemeyer C. Haemostatic aspects in clinical oncology. Hamostaseologie. 2008;28:472–80.PubMedGoogle Scholar
Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994;94:1320–7.CrossRefPubMedPubMedCentralGoogle Scholar
Bromberg ME, Sundaram R, Homer RJ, Garen A, Konigsberg WH. Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost. 1999;82:88–92.PubMedGoogle Scholar
Jiang X, Bailly MA, Panetti TS, Cappello M, Konigsberg WH, Bromberg ME. Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells. J Thromb Haemost. 2004;2:93–101.CrossRefPubMedGoogle Scholar
Ruf W, Disse J, Carneiro-Lobo TC, Yokota N, Schaffner F. Tissue factor and cell signalling in cancer progression and thrombosis. J Thromb Haemost. 2011;9 Suppl 1:306–15.CrossRefPubMedPubMedCentralGoogle Scholar
Rak J, Milsom C, Magnus N, Yu J. Tissue factor in tumour progression. Best Pract Res Clin Haematol. 2009;22:71–83.CrossRefPubMedGoogle Scholar
Strauss HG, Laban C, Lautenschläger C, Buchmann J, Schneider I, Koelbl H, et al. SCC antigen in the serum as an independent prognostic factor in operable squamous cell carcinoma of the cervix. Eur J Cancer. 2002;38(15):1987–91.CrossRefPubMedGoogle Scholar
Mytnik M, Stasko J. D-dimer, plasminogen activator inhibitor-1, prothrombin fragments and protein C—role in prothrombotic state of colorectal cancer. Neoplasma. 2011;58:235–8.CrossRefPubMedGoogle Scholar
Welsh J, Smith JD, Yates KR, et al. Tissue factor expression determines tumour cell coagulation kinetics. Int J Lab Hematol. 2012;34:396–402.CrossRefPubMedGoogle Scholar
Tas F, Kilic L, Bilgin E, et al. Clinical and prognostic significance of coagulation assays in advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2013;23:276–81.CrossRefPubMedGoogle Scholar
Wen-Hui C, Lin-Quan T, Feng-Wei W, Chang-Peng L, Xiao-Peng T, Xiao-Xia H, et al. Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma. BMC Cancer. 2014;14:583.CrossRefGoogle Scholar
Yong-Xin Z, Zhong-Min Y, Jing F, Ying-Jun S, Wei-Li W, Yun-Qing M. High plasma D-dimer level is associated with decreased survival in patients with lung cancer: a meta-analysis. Tumor Biol. 2013;34:3701–4.CrossRefGoogle Scholar
Yamamoto M, Yoshinaga K, Matsuyama A, Iwasa T, Osoegawa A, Tsujita E, et al. Plasma D-dimer level as a mortality predictor in patients with advanced or recurrent colorectal cancer. Oncology. 2012;83:10–5.CrossRefPubMedGoogle Scholar